In other entities such as NSCLC, PD-1high T cells showed a higher capacity for tumor recognition, recruit other immune cells, and are predictive for response and overall survival under PD-1 therapy, which demonstrates that a distinct T cell subtype is needed for response to PD-1/PD-L1 therapy [79]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.